A statement released today by FBR & Co. about Galectin Therapeutics (NASDAQ:GALT) lowers the target price to $2.00
- Updated: October 2, 2016
In a report issued 10/03/2016 FBR & Co. dropped the price target of Galectin Therapeutics (NASDAQ:GALT) from $12.00 to $2.00 reporting a potential upside of 0.77%.
Previously on 9/29/2016, HC Wainwright released a statement for Galectin Therapeutics (NASDAQ:GALT) raised the target price from $0.00 to $1.50 that indicated a possible upside of 0.07%.
Yesterday Galectin Therapeutics (NASDAQ:GALT) traded -7.38% lower at $1.13. The company’s 50-day moving average is $1.86 and its two hundred day average is $1.60. With the last close down -29.44% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time. 1,632,130 shares of Galectin Therapeutics exchanged hands, up from an avg. volume of 607,886
Recent Performance Chart
With a total market value of $0, Galectin Therapeutics has with a one year low of $1.08 and a one year high of $3.25 .
In addition to FBR & Co. reporting its target price, a total of 3 equity analysts have released a research note on the company. The average stock price target is $8.33 with one analyst rating the company a strong buy, 2 brokers rating the stock a buy, zero equity analysts rating the stock a hold, 0 firms rating the company a underperform, and lastly zero equity analysts rating the company a sell.
General Company Details For Galectin Therapeutics (NASDAQ:GALT)
Galectin Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in drug research and development to create therapies for fibrotic disease and cancer. The Company's drug candidates are based on its method of targeting galectin proteins, which are mediators of biologic and pathologic functions. It uses naturally occurring, readily-available plant materials as starting material in manufacturing processes to create complex carbohydrates with specific molecular weights and other pharmaceutical properties. The Company has two product candidates, GR-MD-02 and GM-CT-01. The Company's galectin-3 inhibitor is GR-MD-02. The Company is focusing on development of GR-MD-02 intended to be used in the treatment of liver fibrosis associated with fatty liver disease (NASH), moderate to severe plaque psoriasis and in cancer therapy in combination with immune-system modifying agent(s). GM-CT-01 is a compound that continues to be explored in preclinical studies.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.